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Abstract
The literature on non-genetic peripheral biomarkers for major mental disorders is broad, with conflicting results. An
umbrella review of meta-analyses of non-genetic peripheral biomarkers for Alzheimer’s disease, autism spectrum
disorder, bipolar disorder (BD), major depressive disorder, and schizophrenia, including first-episode psychosis. We
included meta-analyses that compared alterations in peripheral biomarkers between participants with mental
disorders to controls (i.e., between-group meta-analyses) and that assessed biomarkers after treatment (i.e., within-
group meta-analyses). Evidence for association was hierarchically graded using a priori defined criteria against several
biases. The Assessment of Multiple Systematic Reviews (AMSTAR) instrument was used to investigate study quality.
1161 references were screened. 110 met inclusion criteria, relating to 359 meta-analytic estimates and 733,316
measurements, on 162 different biomarkers. Only two estimates met a priori defined criteria for convincing evidence
(elevated awakening cortisol levels in euthymic BD participants relative to controls and decreased pyridoxal levels in
participants with schizophrenia relative to controls). Of 42 estimates which met criteria for highly suggestive evidence
only five biomarker aberrations occurred in more than one disorder. Only 15 meta-analyses had a power >0.8 to detect
a small effect size, and most (81.9%) meta-analyses had high heterogeneity. Although some associations met criteria
for either convincing or highly suggestive evidence, overall the vast literature of peripheral biomarkers for major
mental disorders is affected by bias and is underpowered. No convincing evidence supported the existence of a trans-
diagnostic biomarker. Adequately powered and methodologically sound future large collaborative studies are
warranted.
Introduction
One of the overarching goals of the emerging field of
precision psychiatry is to incorporate advanced technol-
ogies to provide an objective data-driven personalized
approach to the diagnosis and treatment of mental
disorders1,2. However, unlike other medical fields, there is
an acknowledged ‘translational gap’ in psychiatry1,3. In
parallel, the field of biological psychiatry aiming to pro-
vide a neurobiological basis for current mental disorders,
has provided contrasting results, even in pivotal bio-
markers4. Hence, the diagnosis and clinical management
of major mental disorders is still entirely based on psy-
chopathological knowledge, while the treatment of mental
disorders remains predominantly based on ‘trial and
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error’, albeit within the confines of fitting evidence-based
prescription to a clinical profile5.
Over the past two decades the field has witnessed a
remarkable increase in interest on biomarkers for mental
disorders6. In particular, the literature on non-genetic
peripheral biomarkers has grown exponentially, with the
publication of several systematic reviews and meta-
analyses7–12. The identification and validation of bio-
markers for mental disorders are thought to be crucial
steps in the development of precision and biological
psychiatry, and its ultimate incorporation in the current
landscape of psychiatric care is expected to follow1.
However, this change is not translating into meaningful
modifications in clinical practice.
Several reasons may contribute to the contrast between
the overall volume of this literature and the limited
applicability of peripheral biomarkers in current psy-
chiatric practice. For instance, it has been proposed that
conventional psychiatric diagnoses based, for example, on
the Diagnostic and Statistical Manual for Mental Dis-
orders (DSM) may lack biological validity2,13. In this
respect, it has been proposed that similarly to genetic14
and neuroimaging15,16 biomarkers, alterations in periph-
eral biomarkers for major mental disorders may be shared
across distinct diagnostic categories, and thus may have a
transdiagnostic nature6. However, what is a trans-
diagnostic construct in psychiatry remains debated, and
no study has properly assessed the trans-diagnostic nature
of any biomarker with a methodologically sound
approach17.
In addition to the lack of consensus on how to define a
trans-diagnostic construct, a core reason for this transla-
tional gap even in a single disorder may be due to the
presence of several biases including large heterogeneity,
an excess significance bias, as well as a selective reporting
of statistically significant (i.e., ‘positive’) findings without
proper adjustment to multiple confounders. An Umbrella
review systematically evaluates and collects information
from multiple systematic reviews and meta-analyses on all
outcomes of a given topic for which these have been
performed18. Umbrella reviews are particularly suited to
uncover these biases19, as previously demonstrated with
respect to peripheral biomarkers for depression20, bipolar
disorder (BD)20, and schizophrenia21. However, those
previous umbrella reviews have only addressed studies
that have differentiated participants with a specific mental
disorder and healthy controls, and not changes in per-
ipheral biomarkers following treatment for these dis-
orders. Moreover, those umbrella reviews focused on only
one mental disorder each.
Thus, the current work provides a comprehensive
umbrella review of meta-analyses of peripheral bio-
markers for major mental disorders related to high pre-
valence and burden, namely Alzheimer’s disease (AD),
autism spectrum disorder (ASD), BD, major depressive
disorder (MDD), and schizophrenia, including also first-
episode psychosis (FEP) stage. We aimed to re-assess the
presence of bias in this literature and identify biomarkers
that would be supported by most convincing evidence. In
addition, we aimed to identify shared and unique altera-
tions in biomarkers for those major mental disorders
among those supported by either convincing or highly
suggestive evidence. In the current analysis, we con-
sidered both studies that investigated abnormalities in
peripheral biomarkers of mental disorders compared to
controls (i.e., between-group meta-analyses) and ones that
assessed alterations in the levels of peripheral biomarkers
after treatment (i.e., within-group meta-analyses).
Methods
Literature search
We conducted an umbrella review, which is a systematic
collection of multiple systematic reviews and meta-
analyses done in a specific research topic22. The
PubMed/MEDLINE database was searched from incep-
tion to February 17, 2019 for all available meta-analyses
non-genetic peripheral biomarkers for major mental dis-
orders. This search strategy was augmented through (1)
handsearching the reference lists of included articles and
(2) tracking citations of included articles through the
Google Scholar database. The search string used in the
current umbrella review was developed by a professional
librarian and is available in the Supplementary Online
material. The searches, screening, data extraction, and
methodological quality appraisal were independently
conducted by at least two investigators. Disagreements
were resolved through consensus. When a consensus
could not be reached a third investigator (AFC) made the
final decision. An a priori defined protocol was followed
(available upon reasonable request to the corresponding
author of the current manuscript).
Eligibility criteria
We included meta-analyses published in peer-reviewed
journals that assessed and synthesized studies on per-
ipheral biomarkers for adults with AD, ASD, BD, MDD,
Schizophrenia, including FEP. We included studies in
which biomarkers were assayed in participants with a
specific mental disorder compared to controls (i.e.,
between-group meta-analyses), as well as ones which
assessed changes in peripheral biomarkers in any of those
disorders after treatment (i.e., within-group meta-ana-
lyses). Studies published in English were considered for
inclusion. This decision was made because most well-
designed systematic reviews and meta-analyses are pub-
lished in English. We included studies in which diagnoses
of mental disorders were conducted by means of a vali-
dated structured interview based on standard diagnostic
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criteria such as the International Classification of Disease
(ICD) or the Diagnostic and Statistical Manual of Mental
Disorders (DSM). We also considered studies in which a
probable diagnosis of a major depressive episode was
established through a validated screening questionnaire as
well as studies in which a diagnosis of FEP was based on
clinical assessment by a mental health care provider. We
excluded the following types of studies: (1) systematic
reviews without a meta-analytic synthesis of the evidence;
(2) animal studies; (3) studies of other types of biomarkers
(for example, genetic biomarkers); (4) studies that inclu-
ded participants with two or more diagnoses; (5) studies
that included participants with other primary psychiatric
diagnoses (e.g. anxiety disorders); (6) studies that inves-
tigated biomarkers for other purposes (for example, bio-
markers of risk, stage or prognosis)23; (7) studies
conducted in pediatric samples (except from ASD and
FEP); and (8) if there was more than one meta-analysis for
the same biomarker in the same population, we con-
sidered only the largest MA (i.e., the one with the largest
number of included individual studies).
Data extraction
For each eligible reference, we extracted the first author,
year of publication, specific diagnoses assessed, as well as
the number of included studies. We also extracted the
summary effect size (ES) measure of each meta-analysis
considering the ES used in each study. When available,
the following variables were extracted at a study-level:
number of cases, number of controls, sample size, ES, and
study design. In each eligible reference, we only included
the primary analyses due to the expected large amount of
evidence. However, when included references provided
details on the mood state of participants (e.g. mania or
bipolar depression), we also extracted this information at
an individual-study level.
Statistical analysis and methodological quality appraisal
Data were analyzed from March 1, 2019 to October 10,
2019. We estimated ESs and 95% confidence intervals
(CIs) using both fixed and random-effects modeling24.
Due to the anticipated high heterogeneity observed in
meta-analyses of peripheral biomarkers for major mental
disorders, random-effects calculations were considered in
this review. When ESs were not provided as standardized
mean difference (SMD) metrics (e.g., odds ratio), we
converted the primary ESs to SMD25. We also estimated
the 95% prediction interval, which accounts for between-
study heterogeneity and assesses the uncertainty of the
effect that would be expected in a new study addressing
the same association26. For the largest study included in
each meta-analytic estimate, we calculated the standard
error (SE) of the ES. If the SE of the ES is <0.1, then the
95% CI will be <0.20 (i.e., less than the magnitude of a
small ES). We calculated the I2 metric to quantify
between-study heterogeneity. Values ≥50% and ≥75% are
indicative of large and very large heterogeneity, respec-
tively27. To assess evidence of small-study effects, we used
the asymmetry test developed by Egger et al. 28. A P-value
<0.10 in the Egger’s test and the ES of the largest study
being more conservative than the summary random-
effects ES of the meta-analysis were considered indicative
of small-study effects20. We also annotated whether the
association reported in each meta-analytic estimate was
nominally significant at a P < 0.05 level as well as at a P <
0.005 level. The level of P < 0.005 has been proposed as a
more stringent level of significance that could increase the
reproducibility of many fields29.
We also determined whether the meta-analysis had a
statistical power ≥ 80% to detect either a small (i.e., ES ≥
0.2) or a medium (i.e., ES ≥ 0.5). We used the method
described in detail elsewhere30. Finally, we also assessed
evidence of excess of significance bias with the Ioannidis
test31. Briefly, this test estimates whether the number of
studies with nominally significant results (i.e., P < 0.05)
among those included in a meta-analysis is too large
considering their power to detect significant effects at an
alpha level of 0.05. First, the power of each study is esti-
mated with a non-central t distribution. The sum of all
power estimates provides the expected (E) number of
datasets with nominal statistical significance. The actual
observed (O) number of statistically significant datasets is
then compared to the E number using a χ2-based test31.
Since the true ES of a meta-analysis cannot be precisely
determined, we considered the ES of the largest dataset as
the plausible true ES. This decision was based on the fact
that simulations indicate that the most appropriate
assumption is the ES of the largest dataset included in the
meta-analysis32. Excess significance for a single meta-
analysis was considered if P < 0.10 in Ioannidis’s test and
O > E20. We graded the credibility of each association
according to the following categories: convincing (class I),
highly suggestive (class II), suggestive (class III), weak evi-
dence (class IV), and non-significant associations (Table S1).
For evidence supported by either class I or class II
evidence, we used credibility ceilings, which is which is a
method of sensitivity analyses to account for potential
methodological limitations of observational studies that
might lead to spurious precision of combined effect esti-
mates. In brief, this method assumes that every observa-
tional study has a probability c (credibility ceiling) that the
true ES is in a different direction from the one suggested
by the point estimate33. The pooled ESs were estimated
considering a wide range of credibility ceilings. All ana-
lyses were conducted in STATA/MP 14.0 (StataCorp,
USA) with the metan package.
The methodological quality of included systematic
reviews and meta-analyses was also appraised using the
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Assessment of Multiple Systematic Reviews (AMSTAR)
instrument, which has been validated for this purpose34,35.
Scores range from 0 to 11 with higher scores indicating
greater quality. The AMSTAR tool involves dichotomous
scoring (i.e. 0 or 1) of 11 items related to assess metho-
dological rigor of systematic reviews and meta-analyses
(e.g., comprehensive search strategy, publication bias
assessment). AMSTAR scores are graded as high (8–11),
medium (4–7) and low quality (0–3)34.
Results
Our search strategy identified 1161 unique references of
which 991 were excluded after title/abstract screening and
170 underwent full-text review (Fig. 1). Therefore, 110
references met inclusion criteria7–11,36–139, and 60 refer-
ences were excluded with reasons (Table S2). In the 110
included references, there were 81 between-group meta-
analytic estimates for MDD, 79 for AD, 62 for schizo-
phrenia, 45 for ASD, 37 for BD, and 15 for FEP. In
addition, there were 25 within-group meta-analytic esti-
mates for MDD, 13 for Schizophrenia, and 2 for BD
(Mania) (Table S3). In total, there were 247,678 biomarker
measurements estimates in cases and 476,340 assays in
controls across between-group meta-analyses, while there
were 9298 biomarker measurements across within-group
meta-analytic estimates (Table S3). One hundred and
ninety meta-analytic estimates were statistically sig-
nificant at a P-value < 0.05, whilst 109 were significant at a
P-value < 0.005 (Table S3).
Power of meta-analyses
Fifteen between-group meta-analytic estimates had an
estimated power >0.8 to detect a small ES, and 145 meta-
analyses (126 between-group meta-analyses) had an esti-
mated power >0.8 to detect a medium ES (Table S3).
Heterogeneity and prediction intervals
No evidence of large heterogeneity (i.e., I2 < 50%) was
found in 65 meta-analyses (18.1%), whilst 294 (81.9%)
meta-analytic estimates had evidence of large hetero-
geneity (i.e., I2 > 50%). The prediction interval crossed the
null value in 341 (94.9%) meta-analytic associations, while
prediction intervals of 20 (5.0%) meta-analyses did not
cross the null value (Table S3).
Excluded (n=37)
Not a peripheral biomarker (i.e. urine/blood/saliva) (n=13)
Not BD, MDD, SZ, FEP, AD or ASD (n=8)
Not a meta-analysis (n=9)
No control group or no intervenon (n=3)
Meeng abstract (n=1)
No effect size reported (n=1)
Baseline corsol predicng intervenon efficacy (n=1)
Studies meeng criteria (n=133)
Studies where data were extracted (n=110)
Data not extracted owing to more extensive
meta-analysis (n=23)
Citaons idenfied in literature search (n=1159)
Addional records idenfied through other sources (n=2)
Citaons retrieved for more detailed evaluaon (n=170)
Fig. 1 Study flowchart.
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Small-study effects and excess significance bias
Evidence of small-study effects, which is an indication of
publication bias, was observed in 38 (10.6%) meta-ana-
lyses, whilst evidence of excess of significance bias was
verified in 74 (20.6%) meta-analytic estimates (Tables S3).
Grading of the evidence
Only 2 (0.5%) meta-analytic estimates exhibited class I
evidence (83, 119). In euthymic BD participants there was
an increase in basal cortisol awakening levels (Hedges’g=
0.25; 95% CI: 0.15–0.35, P < 0.005) compared to con-
trols87. Participants with schizophrenia presented
decreased Vitamin B6 (pyridoxal) levels relative to con-
trols123. In addition, 42 (11.7%) meta-analytic estimates
were supported by class II evidence, of which 3 were
derived from within-group meta-analyses (Table 1).
Among those estimates, C-reactive protein levels were
increased in euthymic BD, bipolar mania, and in MDD
relative to controls80,102. In addition, soluble interleukin-
(IL)-2 receptor (sIL-2R) levels were increased in MDD
and in schizophrenia relative to controls7,8. Moreover,
levels of antibodies against the N-methyl-D-aspartate
receptor (NMDA-R) were elevated in BD and in schizo-
phrenia relative to controls85. Brain-derived neurotrophic
factor (BDNF) levels were decreased in AD and in
MDD44,110. Furthermore, levels of insulin-like growth
factor-1 (IGF-1) were elevated in bipolar mania and in
MDD relative to controls84. The remaining findings sup-
ported by type II evidence were unique to a single dis-
order (Table 1).
Of the 44 biomarkers supported by either type I or type
II evidence, 37 (84.1%) survived 10% credibility ceilings
(Table 2).
Qualitative methodological appraisal of eligible meta-
analyses
Qualitative methodological appraisal of eligible meta-
analyses through the AMSTAR tool revealed that 49
references were classified as high, 58 as medium, and 3 as
low methodological quality, respectively (Table S4). The
overall methodological quality of included references was
high according to the AMSTAR [(median: 8; IQR= 2
(7–9)] (Table S4).
Discussion
Our umbrella review provided an up-dated synthesis of
the literature of non-genetic peripheral biomarkers for
major mental disorders. We included data from 733,316
biomarker measurements. However, in this vast literature
only two associations met a priori defined criteria for
convincing evidence, whilst 42 meta-analytic estimates
met criteria for highly suggestive evidence. This colla-
borative effort found compelling evidence that overall the
literature on non-genetic peripheral biomarkers has a
high prevalence of different types of bias. In addition, this
umbrella review provides relevant insights for the conduct
of further studies to investigate the associations supported
by most convincing evidence. It should also be noted that
overall the methodological quality of eligible meta-
analyses as assessed with the AMSTAR tool was high,
which provides further credibility to our quantitative
grading of findings.
Associations supported by convincing evidence merit
discussion. First, euthymic participants with BD exhibited a
high cortisol awakening response relative to controls87. This
finding indicates that the hypothalamic–pituitary–adrenal
(HPA) axis is disrupted in BD on a trait-like basis. This
suggests that the HPA axis could be targeted in BD140 to
improve cognitive function, which may be compromised
even during euthymic states141,142. In addition, participants
with schizophrenia exhibited decreased vitamin B6 (pyr-
idoxal) levels compared to controls123. This suggests that
individuals with schizophrenia may present aberrations in
the one-carbon cycle where pyridoxal is a main metabolic
component. An alternative explanation might be the poor
nutrition which frequently affects people with schizo-
phrenia98. This finding is consistent with a recent systematic
review and meta-analysis which provided preliminary evi-
dence that adjunctive pharmacological interventions tar-
geting the one-carbon cycle may improve negative
symptoms in schizophrenia (although the clinical sig-
nificance of this improvement may remain questionable143
and aligns with recent evidence showing that adjunctive
treatment with B-vitamins may improve symptomatic out-
comes in treatment of psychotic disorders144,145).
Importantly, only five biomarkers were found to be
significantly associated with more than one mental dis-
order. Also, the highest class of evidence for these bio-
markers was II. Moreover, no study applied a
methodologically solid approach to assess the trans-
diagnostic nature of any biomarker17. We found periph-
eral elevation on the acute phase reactant, CRP, in BD
(both during euthymia and mania) as well as in MDD
providing evidence that these disorders are at least partly
associated with peripheral inflammation. In addition, the
s-IL-2R was increased in both MDD and schizophrenia
relative to controls. It is noteworthy that IL-2 is a key
cytokine involved in the development, survival and func-
tion of regulatory T cells (TRegs)146,147, and it has been
recently proposed that aberrations in “fine tuning”
immune-regulatory mechanisms may contribute to the
pathophysiology of both MDD and schizophrenia148,149.
Antibodies against the NMDA-R were increased in BD
and schizophrenia. This finding is consistent with the
existence of autoantibodies against the GluN1 subunit of
this receptor in patients with psychotic manifesta-
tions150,151. Furthermore, lower serum BDNF levels were
observed in participants with MDD and AD relative to
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controls. This finding is consistent with the “neurotrophic
hypothesis” of depression152, while parallel lines of evi-
dence suggest that aberrations in BDNF signaling may
contribute to neurodegeneration in AD153. Finally, lower
levels of IGF-1 were observed in bipolar mania and MDD
compared to controls. This finding is consistent with the
modulatory role of glucose-related signaling including the
trophic molecule IGF-1 in hippocampal plasticity154. In
addition, preclinical evidence suggests that IGF-1 may be
involved in the pathophysiology of affective
disorders155,156.
There is an emerging body of literature investigating the
putative role of non-genetic peripheral biomarkers for the
prediction of treatment response in major mental
Table 1 Peripheral biomarkers supported by convincing and highly suggestive evidence across major mental disorders.















Arachidonic acida 101 ↑
BDNF44,110 ↓ ↓
Cortisol168 ↑
Cortisol awakening response119 ↓
Basal cortisol awakeningb 87 ↑
CRP80,102 ↑c ↑





























Lipid peroxidation Markers138 ↑
BDNF brain-derived neurotrophic factor, IGF insulin-like growth factor, IL interleukin, INF interferon, GSH glutathione, GSSG glutathione disulfide, KYN acid kynurenic
acid, Quin quinolinic acid, MDA malondialdehyde, NMDAR N-methyl-D-aspartate receptor antibody seropositivity, NGF nerve growth factor, NT neurotrophin, QUIN
quinolinic acid, sIL-2 Receptor soluble interleukin 2 receptor, TGF transforming growth factor, TNF tumor necrosis factor, 3HK 3-hydroxykynurenine.
aSource: Red blood cells.
bConvincing evidence criteria. Others biomarkers are supported by highly suggestive evidence.
cEuthymia and Mania.
dMania.
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Table 2 Sensitivity analysis using credibility ceilings for the meta-analyses investigating the associations between
biomarkers and Alzheimer disease, autism, bipolar disorder, depression, first episode psychosis, schizophrenia.
Biomarker Credibility ceiling 10% Credibility ceiling 20% Credibility ceiling 30%
Convincing evidence criteria
Bipolar disorder
Basal cortisol awakening87 0.23 (0.07–0.38) 0.19 (−0.01 to 0.40) 0.14 (−0.12 to 0.41)
Schizophrenia
Vitamin B6123 −0.46 (−0.78 to −0.15) −0.46 (−0.95 to 0.02) −0.46 (−1.24 to 0.31)
Highly suggestive evidence criteria
Alzheimer disease
Apolipoprotein E42 −0.20 (−0.35 to −0.04) −0.13 (−0.33 to 0.07) −0.06 (−0.29 to 0.17)
BDNF44 −0.09 (−0.23 to 0.05) −0.03 (−0.14 to 0.08) −0.01 (−0.14 to 0.12)
Copper46 0.17 (0.04–0.30) 0.09 (−0.05 to 0.24) 0.05 (−0.14 to 0.25)
Folic acid59 −0.18 (−0.28 to −0.08) −0.12 (−0.23 to −0.01) −0.08 (−0.23 to 0.07)
Homocysteine59 0.41 (0.28–0.53) 0.40 (0.21–0.59) 0.40 (0.10–0.70)
Vitamin E36 −0.20 (−0.31 to −0.08) −0.13 (−0.26 to −0.01) −0.09 (−0.23 to 0.06)
Autism
5HT64 0.48 (0.26–0.69) 0.35 (0.08–0.62) 0.22 (−0.14 to 0.57)
GSH (fasting)62 −1.42 (−2.51 to −0.32) −1.42 (−3.08 to 0.25) −1.42 (−4.09 to 1.25)
GSSG69 1.07 (0.37–1.78) 1.07 (0.00–2.15) 1.07 (−0.65 to 2.80)
GSSG (fasting)62 1.02 (0.31–1.73) 1.02 (−0.07–2.10) 1.02 (−0.72 to 2.75)
Lipid peroxidation markers138 0.44 (0.09–0.79) 0.34 (−0.07 to 0.75) 0.32 (−0.29 to 0.93)
TGF-Beta 111 0.35 (0.10–0.59) 0.33 (−0.01 to 0.66) 0.31 (−0.18 to 0.80)
Bipolar disorder
IGF184 0.39 (0.03–0.75) 0.39 (−0.16 to 0.94) 0.39 (−0.49 to 1.27)
NMDAR85 0.47 (0.13–0.80) 0.47 (−0.04 to 0.98) 0.47 (−0.35 to 1.29)
NT-382 0.08 (−0.11 to 0.27) −0.01 (−0.18 to 0.16) 0.00 (−0.21 to 0.20)
Uric acid81 0.23 (−0.02 to 0.49) 0.08 (−0.14 to 0.31) 0.03 (−0.20 to 0.27)
CRP* 80 0.20 (0.06–0.34) 0.13 (−0.04 to 0.31) 0.12 (−0.14 to 0.39)
CRP** 80 0.46 (0.23–0.68) 0.44 (0.11–0.78) 0.43 (−0.08 to 0.93)
Depression
BDNF110 −0.18 (−0.30 to −0.05) −0.07 (−0.19 to 0.05) −0.03 (−0.18 to 0.12)
CRP80 0.43 (0.26–0.61) 0.42 (0.16–0.67) 0.42 (0.02–0.82)
Fibroblast growth factor-2111 0.33 (−0.02–0.68) 0.27 (−0.18 to 0.71) 0.19 (−0.36 to 0.74)
Glutamate91 0.29 (0.11–0.46) 0.21 (0.00–0.43) 0.15 (−0.12 to 0.42)
IGF184 0.51 (0.10–0.92) 0.39 (−0.16 to 0.93) 0.23 (−0.45 to 0.91)
IL-6#9 −0.15 (−0.26 to −0.03) −0.10 (−0.23 to 0.02) −0.08 (−0.23 to 0.07)
IL-68 0.35 (0.23–0.48) 0.26 (0.11–0.41) 0.16 (−0.03 to 0.35)
KYNA/3HK75 −0.44 (−0.75 to −0.13) −0.44 (−0.91 to 0.03) −0.44 (−1.20 to 0.32)
KYNA/QUIN75 −0.33 (−0.58 to −0.08) −0.33 (−0.70 to 0.05) −0.33 (−0.93 to 0.28)
KYN-ACID75 −0.21 (−0.33 to −0.09) −0.18 (−0.33 to −0.03) −0.16 (−0.36 to 0.04)
Lipid peroxidation markers#138 0.44 (0.09–0.79) 0.34 (−0.07 to 0.75) 0.32 (−0.29 to 0.93)
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disorders. Surprisingly, no such biomarkers met criteria
for convincing evidence, while only three biomarkers met
criteria for type II evidence. Adiponectin levels in schi-
zophrenia decreased after treatment with second-
generation antipsychotics. This is an interesting finding
since hypoadiponectinemia has been associated with a
wide range metabolic diseases which are common unto-
ward effects of these drugs157,158. In addition, IL-6 levels
decreased after treatment with antidepressants. These
data are consistent with preclinical findings which show
that antidepressants have anti-inflammatory properties
and may also inhibit M1 microglia polarization159. Finally,
lipid peroxidation markers increased after antidepressant
drug treatment for MDD.
It is worth noting that only 15 meta-analytic estimates
had a power >0.80 to detect a small ES. In addition,
previous umbrella reviews indicate that the vast majority
of peripheral biomarker studies are substantially under-
powered20. This may undermine the progress and relia-
bility of this particular field and of neuroscience in general
through the generation of spurious findings160. The “true”
ESs of most non-genetic peripheral biomarkers may be
expected to be small, similarly to those reported in the
genetic literature. Therefore, the design of large, multi-
center studies with an open pre-registered protocol, or the
creation of Consortia, may be a crucial step to assess the
role of peripheral biomarkers in the diagnosis and
treatment of major mental disorders within the frame-
work of precision psychiatry1, as the model adopted by the
Enigma neuroimaging group161, or similarly to other large
collaborative initiatives162. Likewise the creation of bio-
marker scores using a similar rationale as for the gen-
eration of polygenic risk scores may ultimately be a next
step in this field.
Strengths and limitations
It should also be noted that large statistical hetero-
geneity was verified in most included meta-analytic esti-
mates (81.9%). Although this is considered a relevant
indicator of bias in this literature, it may also reflect
genuine heterogeneity, which may occur both within and
between major diagnostic categories163. In addition,
methodological differences of individual studies included
in the assessed meta-analyses may also contribute to
heterogeneity. Those include, for example, the time of
sample selection as well as measurement properties of the
assays (e.g. intra-assay and inter-assay coefficients of
variation). Guidelines to standardize the collection and
measurement of peripheral biomarkers in psychiatry have
been recently proposed164. Furthermore, differences in
sample selection across individual studies might have
contributed to the observed heterogeneity in some meta-
analytic estimates. For example, illness stage and dis-
orders in which mixed presentations are common (e.g.,
Table 2 continued
Biomarker Credibility ceiling 10% Credibility ceiling 20% Credibility ceiling 30%
sIL-2 receptor8 0.35 (0.09–0.61) 0.25 (−0.08 to 0.59) 0.19 (−0.28 to 0.66)
TNF-alpha8 0.15 (0.02–0.28) 0.09 (−0.04 to 0.22) 0.07 (−0.08 to 0.21)
Total cholesterol94 −0.11 (−0.17 to −0.05) −0.09 (−0.16 to −0.02) −0.05 (−0.14 to 0.04)
First episode psychosis
Cortisol awakening response119 −0.43 (−0.72 to −0.14) −0.40 (−0.81 to 0.01) −0.40 (−1.06 to 0.26)
Schizophrenia
Adiponectin#166 −0.20 (−0.32 to −0.08) −0.17 (−0.32 to −0.01) −0.14 (−0.34 to 0.07)
Anti-Gliadin IgA118 0.20 (0.00–0.40) 0.15 (−0.13 to 0.42) 0.15 (−0.30 to 0.59)
Arachidonic acid$101 0.13 (−0.03 to 0.29) 0.06 (−0.11 to 0.23) 0.02 (−0.17 to 0.21)
Cortisol168 0.11 (−0.02 to 0.25) 0.03 (−0.10 to 0.17) 0.00 (−0.17 to 0.17)
Folate105 −0.18 (−0.29 to −0.07) −0.16 (−0.29 to −0.02) −0.13 (−0.32 to 0.07)
MDA109 0.50 (0.09–0.91) 0.43 (−0.02 to 0.88) 0.40 (−0.23 to 1.03)
NGF122 −0.21 (−0.39 to −0.02) −0.11 (−0.31 to 0.08) −0.05 (−0.30 to 0.21)
NMDAR85 0.34 (0.07–0.61) 0.34 (−0.06 to 0.74) 0.34 (−0.30 to 0.98)
sIL-2 receptor7 0.64 (0.06–1.22) 0.64 (−0.24 to 1.52) 0.64 (−0.78 to 2.05)
Symbols: *Euthymia, **Mania, #Prospective study, $Source: Red blood cell.
BDNF brain-derived neurotrophic factor, IGF insulin-like growth factor, IL interleukine, INF interferon, KynA kynurenic acid, Quin quinolinic acid, LDL low-density
lipoproteins, MDA malondialdehyde, NMDAR N-methyl-D-aspartate receptor antibody seropositivity, NGF nerve growth factor, NT neurotrophin, QUIN quinolinic acid,
sIL-2 Receptor soluble interleukin 2 receptor, TGF transforming growth factor, TNF tumor necrosis factor, 3HK 3-hydroxykynurenine.
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bipolar disorder) might have contributed to heterogeneity
across some included meta-analyses. In addition,
approaches to subtype major mental disorders according
to frameworks such as the NIMH Research Domain
Criteria may help to decrease the heterogeneity of this
literature in the future through the study of biologically
valid and more homogenous phenotypes13,163,165.
Conclusion
This umbrella review of non-genetic peripheral bio-
markers for major mental disorders revealed that this
literature is fraught with several biases and is under-
powered. Nevertheless, two associations supported by
convincing evidence and 42 associations supported by
highly suggestive evidence were verified. Most associa-
tions supported by either convincing or highly suggestive
evidence pertained to a single disorder. Future multi-
centric studies with a priori publicly available protocols,
with an ad-hoc methodology to assess the trans-
diagnostic nature of biomarkers17, as well as the subtyp-
ing of these disorders into more biologically valid phe-
notypes, and enough statistical power may improve the
reliability and reproducibility of this field, which is of
relevance for the translation of biological and precision
psychiatry into practice.
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